JPRN-jRCTs032230634招募中2 期
An Exploratory Study to Evaluate the Safety of the High-Intensity Focused Ultrasound(HIFU) in Patients with sagging
Mizuno Hiroshi0 个研究点目标入组 10 人开始时间: 2024年2月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 30age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Men and women 30 years of age or older at the time of obtaining consent.
- •2.Outpatient
- •3.Those who wish to improve facial contour and/or sagging around the eyelids by the treatment using HIFU
- •4.Subjects who have received a explanation of their participation in this study, and who have given written consent of their own free will based on sufficient understanding
- •5.Persons who are judged by the principal investigator to be capable of adequately evaluating the efficacy and safety of this study
排除标准
- •1.Those who using a pacemaker and/or implantable cardiovascular-defibrillator (ICD)
- •2.Pregnant women, lactating women, and women who may be currently pregnant
- •3.Those with impaired wound healing, such as diabetes mellitus
- •4.Atopic dermatitis
- •5.Sunburned within 2 weeks
- •6.Keloid constitution
- •7.Those who previously underwent any aesthetic procedures including thread lift and injectable filler within one month prior to the intervention
- •8.Those who plan to undergo other aesthetic procedures during the study period.
- •9.Those who exhibit progressive sagging face due to aging
- •10.Other subjects who are deemed inappropriate as research subjects by the principal investigator.
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanomaon-small Cell Lung Cancer and Metastatic MelanomaMedDRA version: 20.0 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 100000004864EUCTR2018-003866-14-ESApexigen, Inc.174
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanomaon-small Cell Lung Cancer and Metastatic MelanomaMedDRA version: 20.0Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2018-003866-14-FRApexigen, Inc.174
进行中（未招募）
1 期
A Clinical Study of UC-MSCs for Pediatric Patients with Cerebral PalsyJPRN-jRCT2053210009Ookawa Sumito6
未知
1 期
A Study to Evaluate the Safety and Tolerability of Subcutaneous Treprostinil and Pharmacokinetics of a Novel LY900014 Formulation in Healthy Japanese Subjects (I8B-JE-ITRK)HealthyJPRN-jRCT2080223225Eli Lilly Japan K.K.
进行中（未招募）
1 期
A Study to Evaluate the Safety and Tolerability of JNJ-77730614 When Given as Single and Multiple Doses to Healthy Participants to Assess How Long JNJ 77730614 Stays in the Body (Pharmacokinetics) and How the Body Responds to it (Pharmacodynamics)Healthy VolunteersCTIS2023-505684-36-00Janssen - Cilag International92